Protein A

HCW Biologics’ Founder and CEO Dr. Hing C. Wong Participating in Cambridge Healthtech Institute’s Annual PepTalk Conference 2022

Retrieved on: 
Wednesday, January 19, 2022
Neurodegeneration, Forward-looking statement, Molecular Therapy, Patient, Technology, Tissue, Human, Conference, Intention, Hilton San Diego Bayfront, Inflammation, Protein A, NASDAQ, CEO, Degenerative disease, GLOBE, IND, PST, Health, U.S. Securities and Exchange Commission, Immunosuppression, Pharmacokinetics, Private Securities Litigation Reform Act, Diabetes, Company, HCW, Inflammasome, Immune system, Cell membrane, FDA, Protein, TF, Immunotherapy, Prospectus, Security (finance), Drug discovery, Pharmaceutical industry, Vaccine, Cancer

The conference is taking place virtually and in person at the Hilton San Diego Bayfront in San Diego, California.

Key Points: 
  • The conference is taking place virtually and in person at the Hilton San Diego Bayfront in San Diego, California.
  • HCW Biologics has combined deep understanding of disease-related immunology with its expertise in advanced protein engineering to develop the TOBI discovery platform.
  • HCW Biologics is a transformative immunotherapy company that focuses on inflammaging, a state of unresolved inflammatory responses and chronic inflammation.
  • The invention of HCW Biologics two lead molecules, HCW9218 and HCW9302, was made via the TOBI discovery platform.

HCW Biologics’ Article Published in Cancer Immunology Research Validates Novel Tissue Factor Scaffold Fusion Protein (TOBI™) Discovery Platform

Retrieved on: 
Tuesday, August 17, 2021
Company, Neurodegeneration, HCW, George Washington University School of Medicine & Health Sciences, Founder, Cancer, U.S. Securities and Exchange Commission, Technology, Degenerative disease, Washington University School of Medicine, GLOBE, Immune system, Biopharmaceutical, Diabetes, Ligand, TF, Research, Private Securities Litigation Reform Act, Health, Chemokine, Forward-looking statement, Protein A, Inflammation, Immunotherapy, NK, Cell membrane, NASDAQ, Prospectus, IND, Patient, Acute myeloid leukemia, Cytokine, Protein, Inflammasome, GMP, Security (finance), Drug development, Washington University in St. Louis, Vaccine, Pharmaceutical industry

MIRAMAR, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ: HCWB), an innovative biopharmaceutical company, is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The Company featured its internally-developed Tissue factOr-Based fusIon (TOBITM) discovery platform in a recent research article published online in the peer-reviewed journal Cancer Immunology Research. Using the TOBITM discovery platform, the Company has created novel multi-functional immunotherapeutics to rejuvenate the immune system to reduce the accumulation of senescent cells and suppress the activity of inflammasomes. These fusion immunotherapeutics are comprised of cytokines, chemokines, ligands, receptors, and single-chain antibodies carefully selected and designed to work in tandem to stimulate, inhibit, or target specific immune responses.  

Key Points: 
  • The Company featured its internally-developed Tissue factOr-Based fusIon (TOBITM) discovery platform in a recent research article published online in the peer-reviewed journal Cancer Immunology Research.
  • The key aspect of the unique TOBITM platform is that it uses a novel tissue factor (TF) protein scaffold.
  • HCW Biologics has combined deep understanding of disease-related immunology with its expertise in advanced protein engineering to develop the TOBITM discovery platform.
  • HCW uses its TOBITM discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties for the treatment of inflammaging.

Global Chromatography Resin Market Report 2020-2025 - Increasing Use of Liquid Chromatography-Mass Spectrometry (Lc-Ms) in Analytics and Research

Retrieved on: 
Tuesday, March 23, 2021
Chromatography, Natural sciences, Biology, Affinity chromatography, iMac, Protein A

Factors such as increasing demand for therapeutic antibodies, public-private investment in pharmaceutical & life science research, and rising concern for food safety will drive the chromatography resin market.

Key Points: 
  • Factors such as increasing demand for therapeutic antibodies, public-private investment in pharmaceutical & life science research, and rising concern for food safety will drive the chromatography resin market.
  • The major restraint for the market will be lack of adequate skilled professionals and presence of alternative technologies to chromatography.
  • The high demand for protein A resins and IMAC resins in affinity chromatography technique is expected to drive the chromatography resin market.
  • North America accounts for the largest share of the overall chromatography resin market in terms of both volume and value.

Green Plains Achieves 58% Protein Concentration Milestone

Retrieved on: 
Wednesday, February 24, 2021
Environmentalism, Proteins, Biofuels technology, Biorefinery, Bright green environmentalism, Protein A, Green Plains Inc., IOWA, Aquaculture, Sustainable development, Environmental technology

OMAHA, Neb., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Green Plains Inc. (NASDAQ:GPRE) today announced that development efforts between Green Plains, Fluid Quip Technologies and other innovation partners have led to the production of 58% sustainable Ultra-High Protein at Green Plains Shenandoah, Iowa biorefinery.

Key Points: 
  • OMAHA, Neb., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Green Plains Inc. (NASDAQ:GPRE) today announced that development efforts between Green Plains, Fluid Quip Technologies and other innovation partners have led to the production of 58% sustainable Ultra-High Protein at Green Plains Shenandoah, Iowa biorefinery.
  • The initial Ultra-High Protein system, installed in Shenandoah, Iowa, began production in April 2020 and has seen consistent protein concentration and purity improvement since inception.
  • Green Plains is an innovative producer of Ultra-High Protein and novel ingredients for animal and aquaculture diets to help satisfy a growing global appetite for sustainable protein.
  • The Company also owns a 48.9% limited partner interest and a 2.0% general partner interest in Green Plains Partners LP.

Protein A Resin Market by Product, Type, Application & End-user - Global Forecast to 2025

Retrieved on: 
Monday, February 1, 2021
Proteins, Agarose, Polysaccharides, Protein A, Chemistry, Branches of biology, Physical sciences, Chromatography, Affinity chromatography, Fast protein liquid chromatography

Based on product, the protein A resin market is segmented into agarose-based protein A, glass/silica-based protein A, and organic polymer-based protein A.

Key Points: 
  • Based on product, the protein A resin market is segmented into agarose-based protein A, glass/silica-based protein A, and organic polymer-based protein A.
  • In 2020, the agarose-based protein A segment is expected to command the largest share of the protein A resin market.
  • Based on type, the protein A resin market is segmented into recombinant protein A and natural protein.
  • In 2020, the recombinant protein A segment is expected to command the largest share of the protein A resin market.

Global Protein A Resin Market (2020 to 2025) - Increasing Demand for Biosimilars Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, January 29, 2021
Health, Biotechnology, Proteins, Agarose, Polysaccharides, Protein A, Chemistry, Branches of biology, Physical sciences, Chromatography, Affinity chromatography, Fast protein liquid chromatography

Based on product, the protein A resin market is segmented into agarose-based protein A, glass/silica-based protein A, and organic polymer-based protein A.

Key Points: 
  • Based on product, the protein A resin market is segmented into agarose-based protein A, glass/silica-based protein A, and organic polymer-based protein A.
  • In 2020, the agarose-based protein A segment is expected to command the largest share of the protein A resin market.
  • Based on type, the protein A resin market is segmented into recombinant protein A and natural protein.
  • In 2020, the recombinant protein A segment is expected to command the largest share of the protein A resin market.

Protein A Resin Market worth $1.9 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, January 21, 2021
Proteins, Agarose, Polysaccharides, Branches of biology, Chemistry, Protein A, Physical sciences, Protein methods, Chromatography, Affinity chromatography

Based on product, the protein A resin market is segmented into agarose-based protein A, glass/silica-based protein A, and organic polymer-based protein A.

Key Points: 
  • Based on product, the protein A resin market is segmented into agarose-based protein A, glass/silica-based protein A, and organic polymer-based protein A.
  • In 2020, the agarose-based protein A segment is expected to is expected to command the largest share of the market.
  • Based on type, the market is segmented into recombinant protein A and natural protein A.
  • In 2020, the recombinant protein A segment is expected to is expected to command the largest share of the market.

Protein A Resin Market worth $1.9 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, January 21, 2021
Proteins, Agarose, Polysaccharides, Branches of biology, Chemistry, Protein A, Physical sciences, Protein methods, Chromatography, Affinity chromatography

Based on product, the protein A resin market is segmented into agarose-based protein A, glass/silica-based protein A, and organic polymer-based protein A.

Key Points: 
  • Based on product, the protein A resin market is segmented into agarose-based protein A, glass/silica-based protein A, and organic polymer-based protein A.
  • In 2020, the agarose-based protein A segment is expected to is expected to command the largest share of the market.
  • Based on type, the market is segmented into recombinant protein A and natural protein A.
  • In 2020, the recombinant protein A segment is expected to is expected to command the largest share of the market.

WuXi Biologics adopt Purolite Life Sciences Protein A resin for monoclonal antibody therapies

Retrieved on: 
Thursday, November 5, 2020
Life sciences, Biology, Biotechnology, Natural sciences, Proteins, Agarose, Polysaccharides, Biopharmaceutical, Affinity chromatography, WuXi Biologics, Protein A, Monoclonal antibody

CARDIFF, South Wales, Nov. 5, 2020 /PRNewswire/ -- Purolite Ltd., a global manufacturer of resin-based separation, purification and extraction technologies, today announces that it will supply its Protein A capture resin, Praesto Jetted A50 to WuXi Biologics for immediate use.

Key Points: 
  • CARDIFF, South Wales, Nov. 5, 2020 /PRNewswire/ -- Purolite Ltd., a global manufacturer of resin-based separation, purification and extraction technologies, today announces that it will supply its Protein A capture resin, Praesto Jetted A50 to WuXi Biologics for immediate use.
  • WuXi Biologics, a global company with leading open-access biologics technology, will utilize Praesto Jetted A50 to provide their customers with additional choices for affinity chromatography resins for a range of downstream processes for monoclonal antibody purification.
  • Chris Major, Sales and Marketing Director for Purolite Life Sciences stated, "This is a major step forward for both Purolite Life Sciences and the wider biopharmaceutical industry, and we're extremely proud that WuXi Biologics customers will now have the option of selecting a uniform particle size, Protein A agarose resin.
  • The Praesto line of agarose-based chromatography resins are currently utilized in over 200 screening projects and ongoing clinical trials globally.

WuXi Biologics adopt Purolite Life Sciences Protein A resin for monoclonal antibody therapies

Retrieved on: 
Thursday, November 5, 2020
Life sciences, Biology, Biotechnology, Natural sciences, Proteins, Agarose, Polysaccharides, Biopharmaceutical, Affinity chromatography, WuXi Biologics, Protein A, Monoclonal antibody

CARDIFF, South Wales, Nov. 5, 2020 /PRNewswire/ -- Purolite Ltd., a global manufacturer of resin-based separation, purification and extraction technologies, today announces that it will supply its Protein A capture resin, Praesto Jetted A50 to WuXi Biologics for immediate use.

Key Points: 
  • CARDIFF, South Wales, Nov. 5, 2020 /PRNewswire/ -- Purolite Ltd., a global manufacturer of resin-based separation, purification and extraction technologies, today announces that it will supply its Protein A capture resin, Praesto Jetted A50 to WuXi Biologics for immediate use.
  • WuXi Biologics, a global company with leading open-access biologics technology, will utilize Praesto Jetted A50 to provide their customers with additional choices for affinity chromatography resins for a range of downstream processes for monoclonal antibody purification.
  • Chris Major, Sales and Marketing Director for Purolite Life Sciences stated, "This is a major step forward for both Purolite Life Sciences and the wider biopharmaceutical industry, and we're extremely proud that WuXi Biologics customers will now have the option of selecting a uniform particle size, Protein A agarose resin.
  • The Praesto line of agarose-based chromatography resins are currently utilized in over 200 screening projects and ongoing clinical trials globally.